title: Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.
abstract: The atypical antipsychotic drug olanzapine has been proposed for treatment of dopaminergic psychosis in Parkinson's disease (PD). We report on a 68-year-old patient who developed a severe akinetic-rigid extrapyramidal syndrome, accompanied by additional paranoid symptoms, following olanzapine treatment of optic hallucinosis in PD. Olanzapine may also induce clinically relevant extrapyramidal side effects in PD patients.
authors.affiliation: Klinik für Neurologie, Universität zu Köln, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Rudolf
authors.forename: M
authors.initials: M
authors.lastname: Ghaemi
authors.forename: S
authors.initials: S
authors.lastname: Schmülling
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis; D001569:Benzodiazepines; D003024:Clozapine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006212:Hallucinations / Q000139:chemically induced* / Q000188:drug therapy*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D008297:Male; D000077152:Olanzapine; D010259:Paranoid Disorders / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy*; D010880:Piperidines / Q000009:adverse effects*; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives*; D012642:Selegiline / Q000009:adverse effects*; D012720:Severity of Illness Index
chemical_list: D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D010880:Piperidines; D001569:Benzodiazepines; D012642:Selegiline; D010890:Pirenzepine; D007980:Levodopa; D003024:Clozapine; C026710:budipine; D000077152:Olanzapine